Paul Gubbins

Dr. Paul Gubbins


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
PDF file
PGPaul Gubbins
Paul Gubbins
MKMichael E. Klepser
Michael E. Klepser
AAAlly Dering Anderson
Ally Dering Anderson
KBKarri A. Bauer
Karri A. Bauer
KDKristin M. Darin
Kristin M. Darin
KSKimberly Scarsi
Kimberly Scarsi

19 April 2017 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
LDLindsey E Dayer
Lindsey E Dayer
RSRebecca Shilling
Rebecca Shilling
MVMadalyn Van Valkenburg
Madalyn Van Valkenburg
BMBradley C Martin
Bradley C Martin
PGPaul Gubbins
Paul Gubbins
SHSeth Heldenbrand
Seth Heldenbrand
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

23 April 2014 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
APAmerican College of Clinical Pharmacy
American College of Clinical Pharmacy
PGPaul Gubbins
Paul Gubbins
SMScott T. Micek
Scott T. Micek
MBMelissa Badowski
Melissa Badowski
JCJudy Cheng
Judy Cheng
KSKyle Strnad
Kyle Strnad

18 April 2014 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
KRKelly R. Ragucci
Kelly R. Ragucci
COCindy L. O'BRyant
Cindy L. O'BRyant
KCKristin Bova Campbell
Kristin Bova Campbell
MBMarcia L. Buck
Marcia L. Buck
WDWilliam E. Dager
William E. Dager
EPEmily Prohaska
Emily Prohaska

17 December 2015 in Pharmacy
Verified
Journal Article
Open access
PDF file
PGPaul Gubbins
Paul Gubbins
DRDenise Ragland
Denise Ragland
ACAshley N. Castleberry
Ashley N. Castleberry
NPNalin Payakachat
Nalin Payakachat
Factors associated with family commitment among pharmacists in the south central U.S. are explored. In 2010, a cross-sectional mailed self-administered 70 item survey of 363 active licensed pharmacists was conducted. This analysis includes only 269 (74%) participants who reported being married. Outcome measures were family commitment (need for family commitment, spouse’s family commitment), work-related characteristics (work challenge, stress, workload, flexibility of work schedule), and job and career satisfaction. Married participants’ mean age was 48 (SD = 18) years; the male to female ratio was 1:1; 73% worked in retail settings and 199 (74%) completed the family commitment questions. Females reported a higher need for family commitment than males (p = 0.02) but there was no significant difference in satisfaction with the commitment. Work challenge and work load were significantly associated with higher need for family commitment (p < 0.01), when controlled for age, gender, number of dependents, work status, and practice setting. Higher work challenge was associated with higher career satisfaction. Higher job related stress was associated with lower job satisfaction. High work challenge and work load may negatively impact family function since married pharmacists would need higher family commitment from their counterparts. The impact of work-family interactions on pharmacy career satisfaction should be further investigated.

1 September 2001 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
SPS.R. Penzak
S.R. Penzak
WLW.D. Lawhorn
W.D. Lawhorn
PGPaul Gubbins
Paul Gubbins
Ritonavir is an HIV-1 protease inhibitor that is often used to improve the systemic availability of concurrently administered protease inhibitors by impairing their metabolism through cytochrome P450 (CYP) 3A4. Pharmacodynamic relationships between plasma ritonavir concentrations and efficacy and toxicity have also been described. To date, published high-performance liquid chromatographic (HPLC) methods for the determination of ritonavir in human plasma are often complex, requiring the use of a buffered mobile phase that contains amine-modifiers (i.e. diethylamine, triethylamine). In the method herein, ritonavir was precipitated with acetonitrile plus barium hydroxide and zinc sulphate. Chromatographic separation was accomplished using a C-18 base-deactivated (250 x 4.6 mm I.D., 5 atm particle size) analytic column with a mobile phase composed of acetonitrile:water (52:48, v/v). Quantification was performed at 239 nm. Calibration curves were linear from 0.5-25 microg/ml (R2 > 0.999); percent errors, as a measure of accuracy, were < 12.7%. Intra- and inter-assay relative standard deviations (RSD) were below 12.8%. This method provides a rapid and simple means for the accurate and precise analysis of ritonavir in human plasma. Furthermore, the assay requires neither the use of a buffered mobile phase adjusted to a specific pH, nor the addition of amine modifiers. This method has been successfully used to determine plasma ritonavir concentrations in drug interaction studies.